Drug discovery company STORM Therapeutics reported on Friday that it has raised another GBP14m to bring the total Series A financing to GBP30m.
The new financing includes the new investor, Seroba Life Sciences as well as existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group.
According to STORM, it will use the funds to advance its broad pipeline in preclinical development, accelerate its programmes towards the clinic as well as support its growth as the leading RNA modulating enzymes drug discovery company.
In addition, STORM has named Dr Mark Albertella as VP Translational Oncology. Mark was previously Director of Biology at Medivir AB as well as part of Argenta, OSI Pharmaceuticals, Kudos and AstraZeneca.
On 21 May, STORM Therapeutics' CEO Keith Blundy will give a presenatation at the BioEquity Europe 2019 meeting in Barcelona at 9:00 CEST.
(USD1=GBP0.784529)
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval